Literature DB >> 17288872

The platelet-derived growth factor receptor as a therapeutic target.

Nancy L Lewis1.   

Abstract

Several small molecule tyrosine kinase inhibitors that block the epidermal growth factor receptor and vascular endothelial growth factor receptor function are among the many recently developed targeted anticancer therapeutic agents. Increasing evidence indicates that inhibition of other tumor stromal targets could provide additional and possibly synergistic antitumor effects. This article focuses on the platelet-derived growth factor receptor as one such potential target.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17288872     DOI： 10.1007/s11912-007-0003-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  46 in total

Review 1.  PDGF signaling in cells and mice.

Authors:  Michelle Tallquist; Andrius Kazlauskas
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase.

Authors:  D Wang; H J Huang; A Kazlauskas; W K Cavenee
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

5.  Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma.

Authors:  M P Simon; F Pedeutour; N Sirvent; J Grosgeorge; F Minoletti; J M Coindre; M J Terrier-Lacombe; N Mandahl; R D Craver; N Blin; G Sozzi; C Turc-Carel; K P O'Brien; D Kedra; I Fransson; C Guilbaud; J P Dumanski
Journal:  Nat Genet       Date:  1997-01       Impact factor: 38.330

6.  STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.

Authors:  Kristian Pietras; Michael Stumm; Martine Hubert; Elisabeth Buchdunger; Kristofer Rubin; Carl-Henrik Heldin; Paul McSheehy; Markus Wartmann; Arne Ostman
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

Authors:  Kristian Pietras; Kristofer Rubin; Tobias Sjöblom; Elisabeth Buchdunger; Mats Sjöquist; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

Review 8.  Biology of gastrointestinal stromal tumors.

Authors:  Christopher L Corless; Jonathan A Fletcher; Michael C Heinrich
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

Authors:  Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-X Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  4 in total

1.  Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability.

Authors:  Erik J Hicken; Fred P Marmsater; Mark C Munson; Stephen T Schlachter; John E Robinson; Shelley Allen; Laurence E Burgess; Robert Kirk DeLisle; James P Rizzi; George T Topalov; Qian Zhao; Julie M Hicks; Nicholas C Kallan; Eugene Tarlton; Andrew Allen; Michele Callejo; April Cox; Sumeet Rana; Nathalie Klopfenstein; Richard Woessner; Joseph P Lyssikatos
Journal:  ACS Med Chem Lett       Date:  2013-11-12       Impact factor: 4.345

2.  Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.

Authors:  Nancy L Lewis; Lionel D Lewis; Joseph P Eder; Nandi J Reddy; Feng Guo; Kristen J Pierce; Anthony J Olszanski; Roger B Cohen
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

3.  Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer.

Authors:  Nian-An Luo; Ya-Qi Qu; Guo-Dong Yang; Tao Wang; Ren-Li Li; Lin-Tao Jia; Rui Dong
Journal:  Int J Mol Sci       Date:  2014-11-06       Impact factor: 5.923

Review 4.  Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases.

Authors:  Rong Tang; Wallace Y Langdon; Jian Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.